MARX Biotech Co (ROCO:7731) Operating Income: NT$-139.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7731 MARX Biotech Co Ltd ROCO:7731
8 GF Score
Price NT$4.48
! 5 Warning Signs
View Full Analysis

What is MARX Biotech Co Operating Income?

MARX Biotech Co ROCO:7731 +2.28% 8 Operating Income is NT$-139.5 Mil as of Dec. 2025. GuruFocus rates ROCO:7731 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

MARX Biotech Co's Operating Income for the six months ended in Dec. 2025 was NT$-99.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-139.5 Mil.

Warning Sign:

MARX Biotech Co Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. MARX Biotech Co's Operating Income for the six months ended in Dec. 2025 was NT$-99.2 Mil. MARX Biotech Co's Revenue for the six months ended in Dec. 2025 was NT$326.9 Mil. Therefore, MARX Biotech Co's Operating Margin % for the quarter that ended in Dec. 2025 was -30.36%.

MARX Biotech Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MARX Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 was -25.60%. MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 60.43%.

MARX Biotech Co  (ROCO:7731) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MARX Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-198.49 * ( 1 - 17.67% )/( (602.547 + 673.964)/ 2 )
=-163.416817/638.2555
=-25.60 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=733.009 - 102.507 - ( 27.955 - max(0, 342.364 - 396.345+27.955))
=602.547

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=832.716 - 123.984 - ( 34.768 - max(0, 307.88 - 548.271+34.768))
=673.964

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=209.272/( ( (221.99 + max(219.96, 0)) + (209.158 + max(41.468, 0)) )/ 2 )
=209.272/( ( 441.95 + 250.626 )/ 2 )
=209.272/346.288
=60.43 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(85.926 + 243.589 + 34.948) - (102.507 + 0 + 41.996)
=219.96

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(66.649 + 110.456 + 28.654) - (123.984 + 0 + 40.307)
=41.468

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MARX Biotech Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-99.245/326.931
=-30.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

MARX Biotech Co Operating Income Related Terms

MARX Biotech Co Operating Income Historical Data

* Premium members only.

The historical data trend for MARX Biotech Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co Operating Income Chart

MARX Biotech Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial 16.89 1.89 -14.34 -77.39 -139.46

MARX Biotech Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.02 -41.94 -35.46 -40.21 -99.25
ROCO:7731
8GF Score
MARX Biotech Co Ltd ROCO:7731
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MARX Biotech Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-139.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of NT$-139.5 Mil mean?
MARX Biotech Co (ROCO:7731) has a Operating Income of NT$-139.5 Mil as of Dec. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MARX Biotech Co and its competitors.
Is MARX Biotech Co's Operating Income too high?
MARX Biotech Co's current Operating Income is NT$-139.5 Mil. Overall, MARX Biotech Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's Operating Income compare to competitors?
MARX Biotech Co's Operating Income of NT$-139.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Healthcare Providers & Services company?
A good Operating Income depends on the Healthcare Providers & Services industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MARX Biotech Co and its competitors. MARX Biotech Co's current Operating Income is NT$-139.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current Operating Income of NT$-139.5 Mil. The current Operating Income is NT$-139.5 Mil. MARX Biotech Co's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current Operating Income is NT$-139.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MARX Biotech Co Business Description

Address 5th Floor, No. 655, Bannan Road, Zhonghe district, New Taipei, TWN
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
8GF Score

Get the complete analysis for ROCO:7731

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$4.48
Price